Dizziness ketamine

Memantine (Namenda) [Anti Alzheimer Agent/NMDA Receptor Antagonist] Uses Mod/ evere Alzheimer Dz Action N-methyl-D-aspartate recqjtor antagonist Dose Target 20 mg/d, start 5 mg/d, t 5 mg/d to 20 mg/d, wait >1 wk before t dose use doses if >5mg/d Caution [B, /-] Hqjatic/mild-mod renal impair Disp Tabs, sol SE Dizziness Interactions t Effects W amantadine, carbonic anhydrase inhibitors, dextromethorphan, ketamine, Na bicarbonate t effects W/ any drug, herb, food that alkalinizes urine EMS Use NaHCOs w/ caution OD May cause restlessness, hallucinations, drowsiness, and fainting symptomatic and supportive... 

The chemical agents used by those intent on rape are CHB, short for gamma-hydroxybutyric acid,321 which is a powerful muscle relaxant, ketamine,331 which is used as an anaesthetic, and flunitrazepam,341 which is better known by its trade name Rohypnol and is a powerful antidepressant. They have a variety of street names, such as liquid X, liquid E, and cherry meth for CHB, kit-kat and special K for ketamine, while Rohypnol pills are referred to as roofies, roachies, rope, and roche351 as well as more descriptive names such as circles, forget me pills, and lunch money. These three chemicals will cause a person to become dizzy and then completely unconscious, so much so that when they finally come round many hours later they may find it impossible to recall anything that has happened to them. This amnesia seems to be a permanent loss of memory although some of the victims have flashbacks in the days following the rape. 

In a study of 21 outpatients with refractory neuropathic pain treated with oral ketamine, 17 reported adverse events (20). The most common were light-headedness, dizziness, tiredness, headache, a nervous floating feeling, and bad dreams. The adverse effects were sufficiently important to prevent ten patients from continuing with the trial. 

A randomised double-blind placebo-controlled trial [33 ] investigating ketamine in the management of cancer pain demonstrated no improvement with escalating doses of ketamine (100, 300 and 500 mg) delivered subcutaneously over 24 h. There was, however, a statistically significant increase in adverse events in the ketamine group. This included cognitive disturbances, dizziness, site irritation, somnolence and nausea. 

---